PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Depression

Psychiatric Times. Vol. 30 No. 1
Pages: 1  2  3  
Previous
NEWS 

New Claims and Findings for Ketamine in Severe Depression

By Arline Kaplan | January 17, 2013

Inpatients and hospice

Ketamine is particularly useful for hospitalized depressed and suicidal patients and usually allows for faster discharge. “Ketamine offers patients who are in the hospital with a severe exacerbation of their depression an opportunity to receive an intervention they can’t normally get in an office visit,” Feifel said. Ketamine(Drug information on ketamine) is also starting to be used at UCSD Medical Center for patients on the medical/surgical floors whose profound depression may be interfering with their medical treatment or their ability to consent to treatment.

(MORE: Ketamine, Cum Grano Salis)

At San Diego Hospice and the Institute for Palliative Medicine, another UCSD-affiliated psychiatrist, Scott Irwin, MD, PhD, and his team are evaluating the efficacy and tolerability of oral ketamine for depressed hospice patients. “These are hospice care patients who meet the criteria for clinical depression—about 15% of the patient population,” he said. These patients don’t have the 12 weeks to try a standard antidepressant, and if you look at the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial, 70% of people failed to achieve remission after 12 weeks on a standard antidepressant.”

Irwin said they use psychostimulants as first-line treatment for hospice patients with MDD, but if there is a significant anxiety component, they often use ketamine. “With ketamine, we are finding about a 70% response rate for depression and 100% response rate for anxiety.”

In 2010, Irwin and Iglewicz8 published a report of oral ketamine given to 2 patients in hospice care. Recently, Irwin and his team conducted an open-label trial involving 14 patients, which is in the process of being published. Overall, oral ketamine has been given to some 50 patients. The oral drug is given daily, usually at night. The patients are at home or in a hospice unit. According to Irwin, there are few adverse effects—sleepiness is the primary side effect.

Irwin said that numerous changes have been seen in the patients, and the changes are quite dramatic. “People who weren’t getting out of bed are getting up and doing productive things. They are re-engaging with their families, and they are focusing on things they want to accomplish before they die.”

Pages: 1  2  3  
Previous
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

More like this

Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants

New Medication Strategies for Non-responsive Depressed Patients

Ketamine, Cum Grano Salis

New Claims and Findings for Ketamine in Severe Depression





References

1. Murrough JW, Charney DS. Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep. 2012;14:643-649.

2. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.

3. Luckenbaugh DA, Ibrahim L, Brutsche N, et al. Family history of alcohol dependence and anti­depressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord. 2012;14:880-887.

4. Duncan WC, Sarasso S, Ferrarelli F, et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun 7:1-11; [Epub ahead of print].

5. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939-946.

6. Covvey JR, Crawford AN, Lowe DK. Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother. 2012;46:117-123.

7. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2012 Jul 26; [Epub ahead of print].

8. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med.


 
RELATED TOPICS

Bipolar disorder
Depressive disorders
Dysthymia
Mood disorders
Psychotic affective disorders
Major depressive disorder
Suicide prevention and assessment


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Journey of the Traumatized Hero: Kerouac’s On the Road and Gandhi’s Railroad Ride
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
  • Benefits of CAM Therapies for Dementia
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy